Novo's Decline Reduces Asset Value of Major Shareholder

Novo's significant downturn last year led to a substantial decrease in the asset value of its primary shareholder. Bloomberg posted on X, highlighting the impact on the drugmaker's controlling stakeholder, whose asset value diminished by approximately one-third. This decline underscores the challenges faced by the company amid market fluctuations.